Functional properties of CYP2D6 1 (wild-type) and CYPD26 7 (His324Pro) expressed by recombinant baculovirus in insect cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 3, 1997, Pages 309-318

  Evert, Bernd ^a,c   Eichelbaum, Michel ^a   Haubruck, Heinz ^b   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ELIAS Entwicklungslabor   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Baculovirus expression; CYP2D6; Cytochrome P450; Debrisoquine sparteine polymorphism; Pharmacogenetics; Site directed mutagenesis

Indexed keywords

CYTOCHROME P450 ISOENZYME; MUTANT PROTEIN; RECOMBINANT ENZYME; VIRUS VECTOR;

ALLELE; ANIMAL CELL; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; CYTOCHEMISTRY; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE CONSTRUCT; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN TISSUE; INSECT; LIVER METABOLISM; MUTANT; NONHUMAN; PHENOTYPE; PROTEIN FOLDING;

ANIMALS; BACULOVIRIDAE; CELLS, CULTURED; CYTOCHROME P-450 CYP2D6; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INSECTS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MUTAGENESIS; PHENOTYPE; POLYMORPHISM, GENETIC; RATS; SPODOPTERA;

EID: 0030933378     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004948     Document Type: Article

References (49)

1. Asseffa A, Smith SJ, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ (1989) Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. Arch Biochem Biophys 274:481-490
2. Barnes HJ, Jenkins CM, Waterman MR (1994) Baculovirus expression of bovine cytochrome P450c17 in Sf9 cells and comparison with expression in yeast, mammalian cells, and E. coli. Arch Biochem Biophys 315:489-494
3. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558
4. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA (1995) An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373-384
5. Buters JTM, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP, Gonzalez FJ (1994) cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 22:688-692
6. Buters JTM, Shou M, Hardwick JP, Korzekwa KR, Gonzalez FJ (1995) cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification. Drug Metab Dispos 23:696-701
7. Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JTM, Gelboin HV, Gonzalez FJ, Idle JR, Daly AK (1995) Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 5:234-243
8. Daly AK (1995) Molecular basis of polymorphic drug metabolism. J Mol Med 73:539-553
9. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201
10. Davis TR, Wickham TJ, McKenna KA, Granados RR, Shuler ML, Wood HA (1993) Comparative recombinant protein production of eight insect cell lines. In Vitro Cell Dev Biol 29A:388-390
11. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 23:455-458
12. Ellis SW, Ching MS, Watson PF, Henderson CJ, Simula AP, Lennard MS, Tucker GT, Woods HF (1992) Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharmacol 44:617-620
13. Evert B, Griese EU, Eichelbaum M (1994) A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 350:434-439
14. Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37:3829-3835
15. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/ sparteine polymorphism. Am J Hum Genet 48:943-950
16. Gillam EMJ, Guo Z, Myrtin MV, Jenkins CM, Guengerich FP (1995) Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys 319:540-550
17. Gonzalez FJ, Korzekwa KR (1995) Cytochromes P450 expression systems. Annu Rev Pharmacol Toxicol 35:369-390
18. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988) Characterization of the common defect in humans deficient in debrisoquine metabolism. Nature 331:442-446
19. Harlow E, Lane D (1988) Antibodies: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
20. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J (1995) Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 2:41-62
21. Hink WF, Thomsen DR, Davidson DJ, Meyer AL, Castellino FJ (1991) Expression of three recombinant proteins using baculovirus vectors in 23 insect cell lines. Biotechnol Prog 7:9-14
22. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459
23. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: a study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17216
24. Kalow W (ed) (1992) Pharmacogenetics in Drug Metabolism. Pergamon Press, New York
25. 2+-chelate affinity purification, and characterization of solubility and aggregation. Arch Biochem Biophys 321:277-288
26. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889-904
27. Kitts PA, Ayres DA, Possee RD (1990) Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors. Nucl Acids Res 18:5667-5672
28. Koymans L, Vermeulen NPE, Van Acker SABE, Te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W, Donne-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219
29. Kroemer HK, Eichelbaum M (1995) It's the genes, stupid. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298
30. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32
31. Krynetski EY, Drutsa VL, Kovaleva IE, Luzikov VN (1995) High yield expression of functionally active human liver CYP2D6 in yeast cells. Pharmacogenetics 5:103-109
32. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ (1995) CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys 319:157-167
33. Mikaelian I, Sergeant A (1992) A general and fast method to generate multiple site directed mutations. Nucl Acids Res 20:376
34. Nelson DR (1995) Cytochrome P450 nomenclature and alignment of selected sequences, in Cytochrome P450, structure, mechanism, and biochemistry. Ortiz de Montellano P (ed), Plenum Press, New York and London, pp 575-606
35. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42
36. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378
37. O'Reilly DR, Miller LK, Luckow VA (1994) in Baculovirus expression vectors - A Laboratory Manual. Oxford University Press, New York, Oxford
38. Osikowska-Evers BA, Eichelbaum M (1986) A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver. Life Sci 38:1775-1782
39. Osikowska-Evers B, Dayer P, Meyer UA, Robertz GM, Eichelbaum M (1987) Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers. Clin Pharmacol Ther 41:320-325
40. Paine MJI, Gilham D, Roberts GCK, Wolf CR (1996) Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems. Arch Biochem Biophys 328:143-150
41. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL (1993) Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 3:28-39
42. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26-32
43. Tyndale RF, Gonzalez FJ, Hardwick JP, Kalow W, Inaba T (1990) Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry. Pharmacol Toxicol 67:14-18
44. Vermilion JL, Coon MJ (1978) Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 253:8812-8819
45. Yamazaki S, Sato K, Suhara K, Sakaguchi K, Mihara K, Omura T (1993) Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. J Biochem 114:652-657
46. Yasukochi Y, Masters BSS (1976) Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251:5337-5344
47. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez KJ (1993) Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263
48. Zanger UM, Vilbois F, Hardwick JP, Meyer UA (1988a) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447-5454
49. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA (1988b) Antibodies against human cytochrome P450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256-8260